Rigel Pharmaceuticals (RIGL) Tax Provisions (2021 - 2026)

Rigel Pharmaceuticals' Tax Provisions history runs 4 years deep, the most recent figure standing at $3.0 million for Q1 2026.

• In Q1 2026, Tax Provisions rose 4520.0% year-over-year to $3.0 million; the TTM figure through Mar 2026 stood at -$242.3 million (down 25708.77% YoY), while the FY2025 annual figure was -$245.2 million, down 27931.67% from the prior year.
• Tax Provisions was $3.0 million for Q1 2026 at Rigel Pharmaceuticals, up from -$245.4 million in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $3.0 million in Q1 2026 to a low of -$245.4 million in Q4 2025.
• Historically, Tax Provisions has averaged -$40.2 million across 3 years, with a median of $217000.0 in 2025.
• The sharpest annual moves came in 2025 and 2026: Tax Provisions slumped 27949.15% in 2025, then jumped 4520.0% in 2026.
• A 3-year view of Tax Provisions shows it stood at $881000.0 in 2024, then plunged by 27949.15% to -$245.4 million in 2025, then soared by 101.22% to $3.0 million in 2026.
• The last three Tax Provisions figures came in at $3.0 million (Q1 2026), -$245.4 million (Q4 2025), and -$280000.0 (Q3 2025), per Business Quant data.